Among the putative mechanisms proposed to be common factors in Down syndrome (DS) and Alzheimer's disease (AD) neuropathology, deficits in protein quality control (PQC) have emerged as a unifying mechanism of neurodegeneration. Considering that disturbance of protein degradation systems is present in DS and that oxidized/misfolded proteins require polyubiquitinylation for degradation via the ubiquitin proteasome system, this study investigated if dysregulation of protein polyubiquitinylation is associated with AD neurodegeneration in DS.
Results:
Postmortem brains from DS cases before and after development of AD neuropathology and age-matched controls were analyzed. By selectively isolating polyubiquitinated proteins, we were able to identify specific proteins with an altered pattern of polyubiquitinylation as a function of age. Interestingly, we found that oxidation is coupled with polyubiquitinylation for most proteins mainly involved in PQC and energy metabolism.
Innovation:
This is the first study showing alteration of the polyubiquitinylation profile as a function of aging in DS brain compared with healthy controls. Understanding the onset of the altered ubiquitome profile in DS brain may contribute to identification of key molecular regulators of age-associated cognitive decline.
Conclusions:
Disturbance of the polyubiquitinylation machinery may be a key feature of aging and neurodegeneration. In DS, age-associated deficits of the proteolytic system may further exacerbate the accumulation of oxidized/misfolded/polyubiquitinated proteins, which is not efficiently degraded and may become harmful to neurons and contribute to AD neuropathology. Antioxid. Redox Signal. 26, 280–298.
Get full access to this article
View all access options for this article.
References
1.
AlfanoC, FaggianoS, and PastoreA. The ball and chain of poly-ubiquitin structures. Trends Biochem Sci, 41: 371–385, 2016.
2.
BeckerL, MitoT, TakashimaS, and OnoderaK. Growth and development of the brain in Down syndrome. Prog Clin Biol Res, 373: 133–152, 1991.
3.
Ben-ZviA, MillerEA, and MorimotoRI. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci U S A, 106: 14914–14919, 2009.
4.
ButterfieldDA, Di DomenicoF, SwomleyAM, HeadE, and PerluigiM. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J, 463: 177–189, 2014.
5.
ButterfieldDA, PerluigiM, ReedT, MuharibT, HughesCP, RobinsonRA, and SultanaR. Redox proteomics in selected neurodegenerative disorders: From its infancy to future applications. Antioxid Redox Signal, 17: 1610–1655, 2012.
6.
CalabreseV, SultanaR, ScapagniniG, GuaglianoE, SapienzaM, BellaR, KanskiJ, PennisiG, MancusoC, StellaAM, and ButterfieldDA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal, 8: 1975–1986, 2006.
7.
CastegnaA, AksenovM, AksenovaM, ThongboonkerdV, KleinJB, PierceWM, BoozeR, MarkesberyWR, and ButterfieldDA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med, 33: 562–571, 2002.
8.
CecariniV, DingQ, and KellerJN. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res, 41: 673–680, 2007.
9.
CeniniG, DowlingAL, BeckettTL, BaroneE, MancusoC, MurphyMP, LevineH3rd, LottIT, SchmittFA, ButterfieldDA, and HeadE. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta, 1822: 130–138, 2012.
10.
ChauhanV, JiL, and ChauhanA. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology, 9: 381–389, 2008.
11.
ChenT, ZhouT, HeB, YuH, GuoX, SongX, and ShaJ. mUbiSiDa: A comprehensive database for protein ubiquitination sites in mammals. PLoS One, 9: e85744, 2014.
12.
CisseS, PerryG, Lacoste-RoyalG, CabanaT, and GauvreauD. Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. Acta Neuropathol, 85: 233–240, 1993.
13.
CoskunPE, WyrembakJ, DerberevaO, MelkonianG, DoranE, LottIT, HeadE, CotmanCW, and WallaceDC. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and Down syndrome dementia. J Alzheimers Dis, 20Suppl 2: S293–S310, 2010.
14.
CoxJ, MaticI, HilgerM, NagarajN, SelbachM, OlsenJV, and MannM. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat Protoc, 4: 698–705, 2009.
15.
DantumaNP and BottLC. The ubiquitin-proteasome system in neurodegenerative diseases: Precipitating factor, yet part of the solution. Front Mol Neurosci, 7: 70, 2014.
16.
de HaanJB, CristianoF, IannelloRC, and KolaI. Cu/Zn-superoxide dismutase and glutathione peroxidase during aging. Biochem Mol Biol Int, 35: 1281–1297, 1995.
17.
Di DomenicoF, CocciaR, CoccioloA, MurphyMP, CeniniG, HeadE, ButterfieldDA, GiorgiA, SchininaME, MancusoC, CiniC, and PerluigiM. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta, 1832: 1249–1259, 2013.
18.
Di DomenicoF, PupoG, GiraldoE, BadiaMC, MonllorP, LloretA, Eugenia SchininaM, GiorgiA, CiniC, TramutolaA, ButterfieldDA, VinaJ, and PerluigiM. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Free Radic Biol Med, 91: 1–9, 2015.
19.
Di DomenicoF, PupoG, TramutolaA, GiorgiA, SchininaME, CocciaR, HeadE, ButterfieldDA, and PerluigiM. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: Clues for understanding the development of Alzheimer disease. Free Radic Biol Med, 71: 270–280, 2014.
20.
El AyadiA, StierenES, BarralJM, and BoehningD. Ubiquilin-1 and protein quality control in Alzheimer disease. Prion, 7: 164–169, 2013.
21.
EsserC, AlbertiS, and HohfeldJ. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta, 1695: 171–188, 2004.
22.
FergussonJ, LandonM, LoweJ, DawsonSP, LayfieldR, HangerDP, and MayerRJ. Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci Lett, 219: 167–170, 1996.
23.
GimenoA, Garcia-GimenezJL, AudiL, ToranN, AndaluzP, DasiF, VinaJ, and PallardoFV. Decreased cell proliferation and higher oxidative stress in fibroblasts from Down syndrome fetuses. Preliminary study. Biochim Biophys Acta, 1842: 116–125, 2014.
24.
GoldbergAL. Protein degradation and protection against misfolded or damaged proteins. Nature, 426: 895–899, 2003.
25.
GulesserianT, EngidaworkE, FountoulakisM, and LubecG. Antioxidant proteins in fetal brain: Superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J Neural Transm Suppl. 71–84, 2001.
26.
HamosJE, OblasB, Pulaski-SaloD, WelchWJ, BoleDG, and DrachmanDA. Expression of heat shock proteins in Alzheimer's disease. Neurology, 41: 345–350, 1991.
27.
HeadE, LottIT, WilcockDM, and LemereCA. Aging in Down syndrome and the development of Alzheimer's disease neuropathology. Curr Alzheimer Res, 13: 18–29, 2016.
28.
HeadE, SilvermanW, PattersonD, and LottIT. Aging and Down syndrome. Curr Gerontol Geriatr Res, 2012: 412536, 2012.
29.
HelgueraP, PelsmanA, PiginoG, WolvetangE, HeadE, and BusciglioJ. ets-2 Promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci, 25: 2295–2303, 2005.
30.
HershkoA, CiechanoverA, HellerH, HaasAL, and RoseIA. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A, 77: 1783–1786, 1980.
31.
HorvathS, GaragnaniP, BacaliniMG, PirazziniC, SalvioliS, GentiliniD, Di BlasioAM, GiulianiC, TungS, VintersHV, and FranceschiC. Accelerated epigenetic aging in Down syndrome. Aging Cell, 14: 491–495, 2015.
32.
IharaY, Morishima-KawashimaM, and NixonR. The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med, 2: 1–27, 2012.
33.
IkedaF and DikicI. Atypical ubiquitin chains: New molecular signals. Protein modifications: Beyond the usual suspects' review series. EMBO Rep, 9: 536–542, 2008.
34.
IwaiK, FujitaH, and SasakiY. Linear ubiquitin chains: NF-kappaB signalling, cell death and beyond. Nat Rev Mol Cell Biol, 15: 503–508, 2014.
35.
JiL, ChauhanV, MehtaP, WegielJ, MehtaS, and ChauhanA. Relationship between proteolytically cleaved gelsolin and levels of amyloid-beta protein in the brains of Down syndrome subjects. J Alzheimers Dis, 22: 609–617, 2010.
36.
JiL, ZhaoX, and HuaZ. Potential therapeutic implications of gelsolin in Alzheimer's disease. J Alzheimers Dis, 44: 13–25, 2015.
37.
JiangY, MullaneyKA, PeterhoffCM, CheS, SchmidtSD, Boyer-BoiteauA, GinsbergSD, CataldoAM, MathewsPM, and NixonRA. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A, 107: 1630–1635, 2010.
38.
KellerJN, HanniKB, and MarkesberyWR. Impaired proteasome function in Alzheimer's disease. J Neurochem, 75: 436–439, 2000.
39.
KeveiE and HoppeT. Ubiquitin sets the timer: Impacts on aging and longevity. Nat Struct Mol Biol, 21: 290–292, 2014.
40.
KimW, BennettEJ, HuttlinEL, GuoA, LiJ, PossematoA, SowaME, RadR, RushJ, CombMJ, HarperJW, and GygiSP. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell, 44: 325–340, 2011.
41.
KomanderD and RapeM. The ubiquitin code. Annu Rev Biochem, 81: 203–229, 2012.
42.
KorolchukVI, MenziesFM, and RubinszteinDC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett, 584: 1393–1398, 2010.
43.
KudoT, IqbalK, RavidR, SwaabDF, and Grundke-IqbalI. Alzheimer disease: Correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res, 639: 1–7, 1994.
44.
KulathuY and KomanderD. Atypical ubiquitylation − The unexplored world of poly-ubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol, 13: 508–523, 2012.
45.
LabudovaO, CairnsN, KitzmullerE, and LubecG. Impaired brain glucose metabolism in patients with Down syndrome. J Neural Transm Suppl, 57: 247–256, 1999.
46.
LarsenCN, KrantzBA, and WilkinsonKD. Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry, 37: 3358–3368, 1998.
47.
LeckerSH, GoldbergAL, and MitchWE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol, 17: 1807–1819, 2006.
48.
LiW and YeY. Poly-ubiquitin chains: functions, structures, and mechanisms. Cell Mol Life Sci, 65: 2397–2406, 2008.
49.
LilienbaumA. Relationship between the proteasomal system and autophagy. Int J Biochem Mol Biol, 4: 1–26, 2013.
50.
Lopez SalonM, MorelliL, CastanoEM, SotoEF, and PasquiniJM. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res, 62: 302–310, 2000.
51.
LottIT, HeadE, DoranE, and BusciglioJ. Beta-amyloid, oxidative stress and Down syndrome. Curr Alzheimer Res, 3: 521–528, 2006.
52.
MenziesFM, FlemingA, and RubinszteinDC. Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci, 16: 345–357, 2015.
53.
NixonRA and YangDS. Autophagy failure in Alzheimer's disease—Locating the primary defect. Neurobiol Dis, 43: 38–45, 2011.
54.
NunomuraA, PerryG, PappollaMA, FriedlandRP, HiraiK, ChibaS, and SmithMA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol, 59: 1011–1017, 2000.
55.
OsakaH, WangYL, TakadaK, TakizawaS, SetsuieR, LiH, SatoY, NishikawaK, SunYJ, SakuraiM, HaradaT, HaraY, KimuraI, ChibaS, NamikawaK, KiyamaH, NodaM, AokiS, and WadaK. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet, 12: 1945–1958, 2003.
56.
PaganoG and CastelloG. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol, 724: 291–299, 2012.
57.
PerluigiM, Di DomenicoF, and ButterfieldDA. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis, 84: 39–49, 2015.
58.
PerluigiM, di DomenicoF, FioriniA, CoccioloA, GiorgiA, FoppoliC, ButterfieldDA, GiorlandinoM, GiorlandinoC, SchininaME, and CocciaR. Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid. Proteomics Clin Appl, 5: 167–178, 2011.
59.
PerluigiM, PupoG, TramutolaA, CiniC, CocciaR, BaroneE, HeadE, ButterfieldDA, and Di DomenicoF. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta, 1842: 1144–1153, 2014.
60.
RadivojacP, VacicV, HaynesC, CocklinRR, MohanA, HeyenJW, GoeblMG, and IakouchevaLM. Identification, analysis, and prediction of protein ubiquitination sites. Proteins, 78: 365–380, 2010.
61.
RappsilberJ, MannM, and IshihamaY. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc, 2: 1896–1906, 2007.
62.
RoperRJ and ReevesRH. Understanding the basis for Down syndrome phenotypes. PLoS Genet, 2: e50, 2006.
63.
RothenbergC and MonteiroMJ. Ubiquilin at a crossroads in protein degradation pathways. Autophagy, 6: 979–980, 2010.
64.
SawaA. Neuronal cell death in Down's syndrome. J Neural Transm Suppl, 57: 87–97, 1999.
65.
SetsuieR and WadaK. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int, 51: 105–111, 2007.
66.
SilvaGM, FinleyD, and VogelC. K63 poly-ubiquitination is a new modulator of the oxidative stress response. Nat Struct Mol Biol, 22: 116–123, 2015.
67.
StierenES, El AyadiA, XiaoY, SillerE, LandsverkML, OberhauserAF, BarralJM, and BoehningD. Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J Biol Chem, 286: 35689–35698, 2011.
68.
TanakaK and MatsudaN. Proteostasis and neurodegeneration: The roles of proteasomal degradation and autophagy. Biochim Biophys Acta, 1843: 197–204, 2014.
69.
TramutolaA, PupoG, Di DomenicoF, BaroneE, ArenaA, LanzillottaC, BroekaartD, BlarzinoC, HeadE, ButterfieldD, and PerluigiM. Activation of p53 in Down syndrome and in the Ts65Dn mouse brain is associated with a pro-apoptotic phenotype. J Alzheimers Dis, 52: 359–371, 2016.
70.
TriplettJC, SwomleyAM, CaiJ, KleinJB, and ButterfieldDA. Quantitative phosphoproteomic analyses of the inferior parietal lobule from three different pathological stages of Alzheimer's disease. J Alzheimers Dis, 49: 45–62, 2015.
71.
WickliffeKE, WilliamsonA, MeyerHJ, KellyA, and RapeM. K11-linked ubiquitin chains as novel regulators of cell division. Trends Cell Biol, 21: 656–663, 2011.
72.
WisemanFK, Al-JanabiT, HardyJ, Karmiloff-SmithA, NizeticD, TybulewiczVL, FisherEM, and StrydomA. A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Nat Rev Neurosci, 16: 564–574, 2015.
73.
WolfeDM, LeeJH, KumarA, LeeS, OrensteinSJ, and NixonRA. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci, 37: 1949–1961, 2013.
74.
XuP, DuongDM, SeyfriedNT, ChengD, XieY, RobertJ, RushJ, HochstrasserM, FinleyD, and PengJ. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell, 137: 133–145, 2009.
75.
ZanaM, JankaZ, and KalmanJ. Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease. Neurobiol Aging, 28: 648–676, 2007.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
